Thyrotoxicosis and I¹³¹ : TMC Experience

Original article


Aisha Lazreg

Department of Medicine- Al Fateh University, Tripoli -Libya. Endocrine Department, Tripoli Medical Centre, Tripoli-Libya

JMJ Vo1.7 No.1 (Spring) 2007:39-41


A descriptive retrospective survey of 156 thyrotoxic patients, 108 women, 48 men aged between 20-79 with a mean of 51±12 years given an empirical dose of I¹³¹ ranging between111mbq to 599.4 mbq, with a mean of 319.1± 68.6 mbq, from 1982 -2001 to assess response, remission rate after first dose, remission rate after second dose, development of hypothyroidism at 1 year, 5 years and 10 years after the dose. There was 112 patients (71.79 %) with graves´ disease, 10 patients (6.41 %) with toxic multinodular goiter, 6 patients ( 3.84% ) with toxic nodule , 28 patient (17.9% ) unclassified , 6 months after the first dose 49% were euthyroid, 16.5% developed hypothyroidism ,16%failed to respond and subsequently needed a second dose , 14% were lost from follow up , 2.6% did not complete 6 months, 1.3% continued on Carbimazole, 1.6% were for a second dose, no acute complications was documented, for the 26 patients needed a second dose follow up after 6 month 73% were euthyroid, 15%were hypothyroid, 10% were for a third dose(still thyrotoxic), overall development of hypothyroidism at one year was 40%, after 5 years 72% and after 10 years was 84%. These results conclude that radioactive iodine therapy for hyperthyroidism is a safe, satisfactory and a low cost method assuming that the patients are continued on life long follow up.

Keywords: Thyrotoxicosis, Radioactive iodine, Empirical dose, Hypothyroidism